FDA Approves New Indication for Merck's Hyzaar

The FDA has approved a new indication for Merck's Hyzaar, a fixed-dose combination antihypertensive drug.

Hyzaar (losartan potassium-hydrochlorothiazide) is now indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (LVH).

In March 2003, the FDA approved the same indication for Merck's antihypertensive drug Cozaar (losartan potassium tablets). Hyzaar and Cozaar are currently the only angiotensin II receptor blockers to be indicated to reduce the risk of stroke in patients with hypertension and LVH.